KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Equity Ratio: 2011-2024

Historic Equity Ratio for Supernus Pharmaceuticals (SUPN) over the last 14 years, with Dec 2024 value amounting to 0.76.

  • Supernus Pharmaceuticals' Equity Ratio fell 1.43% to 0.74 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.74, marking a year-over-year decrease of 1.43%. This contributed to the annual value of 0.76 for FY2024, which is 4.97% up from last year.
  • As of FY2024, Supernus Pharmaceuticals' Equity Ratio stood at 0.76, which was up 4.97% from 0.72 recorded in FY2023.
  • Supernus Pharmaceuticals' Equity Ratio's 5-year high stood at 0.76 during FY2024, with a 5-year trough of 0.48 in FY2021.
  • Moreover, its 3-year median value for Equity Ratio was 0.72 (2023), whereas its average is 0.67.
  • Per our database at Business Quant, Supernus Pharmaceuticals' Equity Ratio decreased by 3.50% in 2020 and then soared by 38.56% in 2023.
  • Supernus Pharmaceuticals' Equity Ratio (Yearly) stood at 0.50 in 2020, then decreased by 2.47% to 0.48 in 2021, then rose by 7.77% to 0.52 in 2022, then skyrocketed by 38.56% to 0.72 in 2023, then grew by 4.97% to 0.76 in 2024.